US Edition
Traws advances development plans for rigosertib in RDEB-SCC
Summary by Epidermolysis Bullosa News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Traws advances development plans for rigosertib in RDEB-SCC
Traws Pharma said it will advance development of skin cancer therapy rigosertib, after data showed the therapy led to a partial or complete treatment response for four recessive dystrophic epidermolysis bullosa (RDEB) patients with advanced forms of the skin cancer squamous cell carcinoma (SCC). The data came from two ongoing, investigator-initiated Phase 2 trials — one running in the U.S. (NCT04177498) and the other in Austria (NCT03786237) — w…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
